-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $17

Benzinga·06/08/2026 14:18:57
Listen to the news
Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $20 to $17.